Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nurexone Biologic Inc (NRX.VN)

Nurexone Biologic Inc (NRX.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 61,663
  • Shares Outstanding, K 90,681
  • Annual Sales, $ 0 K
  • Annual Income, $ -5,043 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 0.58
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 30.69
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.08
  • Most Recent Earnings $-0.02 on 11/26/25
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (N/A)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING:

    TSX Biotechnology

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.610 unch
on 12/12/25
0.760 -19.74%
on 11/24/25
-0.090 (-12.86%)
since 11/12/25
3-Month
0.610 unch
on 12/12/25
1.140 -46.49%
on 09/16/25
-0.290 (-32.22%)
since 09/12/25
52-Week
0.540 +12.96%
on 01/30/25
1.140 -46.49%
on 09/16/25
-0.170 (-21.79%)
since 12/12/24

Most Recent Stories

More News
NurExone Plans Small-Scale of ExoPTEN Clinical Manufacturing in Preparation for FUTURE First in Human USE Pathways

TORONTO and HAIFA, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”), a preclinical-biotechnology company...

NRX.VN : 0.610 (-10.29%)
NRXBF : 0.4670 (-5.96%)
NurExone Biologic Inc. Announces Third Quarter 2025 Financial Results and Provides Corporate Update

TORONTO and HAIFA, Israel, Nov. 28, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc.  (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”), a preclinical-stage biotechnology...

NRX.VN : 0.610 (-10.29%)
NRXBF : 0.4670 (-5.96%)
NurExone Secures over C$3.18 Million Through Accelerated Warrant Exercises

TORONTO and HAIFA, Israel, Nov. 12, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”) is pleased to announce that, further...

NRX.VN : 0.610 (-10.29%)
NRXBF : 0.4670 (-5.96%)
NurExone Accepted into ARMI’s BioFab Startup Lab Strengthening U.S Position in Regenerative Manufacturing

TORONTO and HAIFA, Israel, Nov. 03, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”) announced today that it has been accepted...

NRX.VN : 0.610 (-10.29%)
NRXBF : 0.4670 (-5.96%)
NurExone Invited Presenter at Precision EV Forum in Cambridge, UK

TORONTO and HAIFA, Israel, Oct. 21, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) a biopharmaceutical company developing...

NRX.VN : 0.610 (-10.29%)
NRXBF : 0.4670 (-5.96%)
NurExone Demonstrates Reproducible, Dose-Dependent Vision Recovery in Preclinical Glaucoma Model

TORONTO and HAIFA, Israel, Oct. 08, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”) a biopharmaceutical company developing...

NRX.VN : 0.610 (-10.29%)
NRXBF : 0.4670 (-5.96%)
NurExone Planning to Establish First U.S. Commercial Manufacturing Facility in Indiana

TORONTO and HAIFA, Israel and INDIANAPOLIS, Sept. 16, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical...

NRX.VN : 0.610 (-10.29%)
NRXBF : 0.4670 (-5.96%)
NurExone Biologic Announces Corporate Updates including Israel Patent Grant and Private Placement Closing

TORONTO and HAIFA, Israel, Sept. 11, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”), a pioneering biopharmaceutical company...

NRX.VN : 0.610 (-10.29%)
NRXBF : 0.4670 (-5.96%)
NurExone Receives U.S. Patent Allowance for Exosome Manufacturing, Strengthening Supply Chain Readiness

TORONTO and HAIFA, Israel, Sept. 08, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a pioneering biopharmaceutical company...

NRX.VN : 0.610 (-10.29%)
NRXBF : 0.4670 (-5.96%)
NurExone Biologic Inc. Announces Second Quarter 2025 Financial Results

TORONTO and HAIFA, Israel, Aug. 28, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc.  (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”), a preclinical-stage biotechnology...

NRX.VN : 0.610 (-10.29%)
NRXBF : 0.4670 (-5.96%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strongest short term outlook on maintaining the current direction.

Relative Strength just crossed below 30%. The market has entered oversold territory.

See More Share

Business Summary

NurExone Biologic Inc is a company that focuses on developing biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Their primary product is ExoTherapy, which is an exosome therapy production platform. The company has two business lines. Firstly, it is developing...

See More

Key Turning Points

3rd Resistance Point 0.727
2nd Resistance Point 0.703
1st Resistance Point 0.657
Last Price 0.610
1st Support Level 0.587
2nd Support Level 0.563
3rd Support Level 0.517

See More

52-Week High 1.140
Fibonacci 61.8% 0.911
Fibonacci 50% 0.840
Fibonacci 38.2% 0.769
Last Price 0.610
52-Week Low 0.540

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar